Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has
launched over-the-counter (OTC) Lansoprazole delayed-release capsules in
the U.S. market on May 18, 2012, following Dr. Reddy's ANDA approval by
the United States Food & Drug Administration (USFDA).
Dr. Reddy's will market the product under store brand labels in the U.S.
market. The product is the bioequivalent version of Novartis Consumer
Health's Prevacid®24 HR capsule which received Rx-to-OTC switch approval
with 3 year exclusivity from the FDA on March 18, 2009. The Prevacid®24
HR capsule market had brand sales of approximately $115 million for the
twelve months ending March 2012 according to SymphonyIRI InfoScan
Reviews™.
Dr. Reddy's Lansoprazole Capsule in 15 mg strength is available in 14,
28 and 42 count pack size.